INNOVATE Corp.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
(1) Operating Segments and Related Information
- Operating Segments and Related Information
The Company currently hasone primary reportable geographic segment - United States, and primarily all revenue is derived in the United States, and primarily all PP&E and intangible assets reside in the United States. The reportable segments are identified based on the nature of the services and products provided, the organizational structure, and the internal reporting system used by the Chief Operating Decision Maker ("CODM") to assess performance and allocate resources. The Company hasthree reportable operating segments, plus the Other segment, based on management’s organization of the enterprise - Infrastructure, Life Sciences, Spectrum, and Other. The Company also has a Non-Operating Corporate segment. All inter-segment transactions are eliminated on consolidation. There are no inter-segment revenues. Refer to Note 1. Organization and Business for additional information on the organizational structure of the business and Note 3. Revenue and Contracts in Process for additional information on the products and services offered by each segment.
The Chief Operating Decision Maker ("CODM") for the Company is the Interim CEO, Paul Voigt. The CODM is primarily responsible for allocating resources at all levels that do not require board approval. The CODM monitors the performance of each segment and is responsible for making strategic decisions regarding capital and resource allocation. The CODM uses a combination of monthly reports, which detail revenue and income (loss) from operations, and quarterly summaries, which include detailed breakdowns of each segment's income (loss) from operations, to evaluate segment performance, allocate resources and make strategic decisions. These financial metrics are used to view operating trends, perform analytical comparisons and benchmark performance between periods and to monitor budget-to-actual variances on a monthly basis. The primary GAAP metric used by the CODM in assessing segment performance is income (loss) from operations.
Financial information, including revenue and expenses, with respect to the Company’s operating segments, is as follows (in millions):
| Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE | |
|---|---|---|---|---|---|---|
| Revenue | $1,071.6 | $9.8 | $25.7 | $— | $— | $1,107.1 |
| Cost of revenue | 880.4 | 6.4 | 11.5 | — | — | 898.3 |
| Selling, general and administrative expenses | 123.1 | 17.1 | 7.3 | 12.7 | — | 160.2 |
| Depreciation and amortization | 12.0 | 0.4 | 5.1 | 0.1 | — | 17.6 |
| Other operating (income) loss (1) | (9.6) | — | 0.4 | 0.2 | — | (9.0) |
| Income (loss) from operations | $65.7 | $(14.1) | $1.4 | $(13.0) | $— | $40.0 |
| Other data: | ||||||
| Capital expenditures (2) | $17.6 | $— | $1.4 | $— | $— | $19.0 |
| Investments (3) | $— | $1.8 | $— | $1.8 | $— | $3.6 |
| Total assets | $683.6 | $11.9 | $178.9 | $16.7 | $— | $891.1 |
(1) Other operating income at our Infrastructure segment for the year ended December 31, 2024, related mainly to a gain on a lease modification and a net gain on the sale and disposal of various properties.
(2) Capital expenditures reflect cash expenditures.
(3) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of December 31, 2024.
| Infrastructure | Life Sciences | Spectrum | Non-Operating Corporate | Other and Eliminations | INNOVATE | |
|---|---|---|---|---|---|---|
| Revenue | $1,397.2 | $3.3 | $22.5 | $— | $— | $1,423.0 |
| Cost of revenue | 1,192.6 | 2.6 | 11.8 | — | — | 1,207.0 |
| Selling, general and administrative expenses | 126.0 | 15.2 | 9.0 | 15.8 | 2.0 | 168.0 |
| Depreciation and amortization | 14.4 | 0.5 | 5.2 | 0.1 | — | 20.2 |
| Other operating (income) loss (1) | (0.2) | — | (0.1) | 0.5 | 1.1 | 1.3 |
| Income (loss) from operations | $64.4 | $(15.0) | $(3.4) | $(16.4) | $(3.1) | $26.5 |
| Other data: | ||||||
| Capital expenditures (2) | $16.6 | $0.5 | $1.0 | $0.3 | $— | $18.4 |
| Investments (3) | $— | $1.8 | $— | $— | $— | $1.8 |
| Total assets | $851.4 | $8.3 | $176.6 | $7.3 | $— | $1,043.6 |
(1) Other operating loss for the year ended December 31, 2023, primarily consisted of a write-off of prepaid rent at the Other segment and an impairment of leasehold improvements at the Non-Operating Corporate segment for unutilized office space.
(2) Capital expenditures reflect cash expenditures.
(3) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of December 31, 2023.
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Reconciliation of the consolidated segment income from operations to consolidated loss from operations before income taxes: | ||
| Income from operations | $40.0 | $26.5 |
| Interest expense | (74.5) | (68.2) |
| Loss from equity investees | (2.3) | (9.4) |
| Other income, net | 3.4 | 16.7 |
| Loss from operations before income taxes | $(33.4) | $(34.4) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.